[Curative antifungal treatment of invasive pulmonary aspergillosis].
Pulmonary invasive aspergillosis is a frequent and poor prognosis complication of immunodeficiency and prolonged neutropenia. Its treatment is usually based on amphotericin given as intravenous infusion at 1 to 1.25 mg/kg/d. Use of lipid carriers give the opportunity to administrated higher dose, 5 mg/kg/d, with respect of renal function and good results in the primarily study. Intraconazole is now a good therapy after amphotericin, in the second time of disease.
Andrès
E
E
Service de pneumologie, CHU de Strasbourg.
Courouau
F
F
Kurtz
J E
JE
Limacher
J M
JM
Quoix
E
E
D000666:Amphotericin B / Q000008:administration & dosage / Q000627:therapeutic use; D000935:Antifungal Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001228:Aspergillosis / Q000188:drug therapy*; D006801:Humans; D017964:Itraconazole / Q000627:therapeutic use; D008172:Lung Diseases, Fungal / Q000188:drug therapy*
D000935:Antifungal Agents; D017964:Itraconazole; D000666:Amphotericin B